Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
NCT01999101
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
DRUG:
Px-104
Sponsor
Phenex Pharmaceuticals AG
Collaborators
[object Object]